Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Interventions: Drug: Bardoxolone methyl; Drug: Bardoxolone methyl; Drug: Bardoxolone methyl; Drug: Bardoxolone methyl; Drug: Bardoxolone methyl; Drug: Bardoxolone methyl; Drug: Bardoxolone methyl; Drug: Gemcitabine; Drug: Placebo; Drug: Bardoxolone methyl
Sponsors: Biogen
Terminated

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 28, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments